---
title: "SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum | SPRC Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287920812.md"
description: "SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum | SPRC Stock News"
datetime: "2026-05-28T04:40:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287920812.md)
  - [en](https://longbridge.com/en/news/287920812.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287920812.md)
generator: "portal-rs"
---

# SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum | SPRC Stock News

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum | SPRC Stock News

### Related Stocks

- [SPRC.US](https://longbridge.com/en/quote/SPRC.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Scisparc posts audited 2025 net loss of USD 12.56 million](https://longbridge.com/en/news/296357022.md)
- [SciSparc subsidiary NeuroThera Labs raises C$5.4 million in private placements](https://longbridge.com/en/news/296225798.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**